MARKET WIRECNBC • 2h ago
Here are 3 big things we're watching in the stock market in the week aheadThe market could use a few victories in the days ahead, which will be filled with more earnings, an election, and jobs data.
Why MAZE Stock advanced +0.63% Today — RQD Quant Desk Flash
$31.93 +0.63% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $31.91
Maze Therapeutics Inc. (MAZE) carries a Roarable Rating of D (Sell) with 45/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE D • SELL / AVOID
Cap $1.77B
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $31.90 (-0.08%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 7/20 (D-) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (45/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-6.3% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERSELL / AVOID • D
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw D- · Rk D+
Each axis scored 0–20
12M PRICE TARGET CONE-5.9% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for MAZE)Realized 20D OHLCV Swing Band: ±11.5%
Deterministic 5-Pillar Attribution (45/100 Composite)
🔍 WHY MAZE SCORES 45/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Whale & Options Positioning+13/20 pts (29% of score)
20D Institutional Volume Accumulation (±11.5% realized swing band)
▲ #2 Bullish Driver: Macro Regime Fit+12/20 pts (27% of score)
FRED Regime × Technicals: 31% of 52W Range • RSI-14 at 63.3 (BULLISH MOMENTUM)
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade E$27.11+1.5% Next Q
37
Q2 (-2Q)Grade D$27.53+12.6% Next Q
40
Q3 (-1Q)Grade D$31.01+3% Next Q
42
CurrentGrade D$31.93-6.3% Hist 90D α
45
Trajectory: E (37) → D (45)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a MAZE Turnaround Squeeze
While MAZE currently carries a cautious 45/100 (D) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($27.49) and Max Pain ($33.53) forces dealer call-delta covering toward $56.33.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $MAZE• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “MAZE Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why MAZE Stock advanced +0.63% Today — RQD Quant Desk Flash
Maze Therapeutics Inc. (MAZE) advanced +0.63% to $31.93, trading at 31% of its 52-week range ($21.95 – $53.65). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 31% of its 52-week range ($21.95 – $53.65) with RSI-14 at 63.3 (BULLISH MOMENTUM).
- ▸Volatility Profile: Historical 20-day realized swing band of ±11.5% around $31.93 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D (Sell) backed by 52% gross margin and $0 annual free cash flow.
Live MAZE Headlines & Catalysts
MARKET WIRECNBC • 3h ago
Democratic Rep. Stevens endorses Rogers over El-Sayed in Michigan Senate electionHaley Stevens had lost the Democratic nomination for Senate in Michigan to Abdul El-Sayed earlier this year.
RISK WATCHReuters • 4h ago
Israeli strikes kill eight people in Gaza - medics say - ReutersIsraeli strikes kill eight people in Gaza - medics say Reuters
MARKET WIREReuters • 5h ago
Russia's FSB says minor detained over park attack threat after US tip-off - ReutersRussia's FSB says minor detained over park attack threat after US tip-off Reuters
MARKET WIREReuters • 6h ago
Iran, Qatari mediators hold third day of talks to end US-Iran war - ReutersIran, Qatari mediators hold third day of talks to end US-Iran war Reuters
CATALYSTReuters • 7h ago
Qatar surges, bucking Gulf market slide on Iran war concerns - ReutersQatar surges, bucking Gulf market slide on Iran war concerns Reuters
MARKET WIREReuters • 7h ago
OPEC+ keeps December oil output targets steady ahead of tougher call for 2027 - ReutersOPEC+ keeps December oil output targets steady ahead of tougher call for 2027 Reuters
MARKET WIREReuters • 7h ago
German ministers pledge tough action after rioters damage stores in Frankfurt - ReutersGerman ministers pledge tough action after rioters damage stores in Frankfurt Reuters
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring MAZE)
- ✓Walkthrough of MAZE's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
MAZE // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +20.13%📐 HORIZONTAL RANGE
2026-10-30O $31.93H $32.46L $31.23C $31.93VOL 327.1K
RES: $33.61SUP: $19.16SMA50: $27.49SMA200: $31.85
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
MAZE Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on MAZE today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for MAZE. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for MAZE today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (MAZE)
Health Care Rank #473 of 1016
⚔️ NVAX vs MAZE Full Matrix →
1. Head-to-Head Health Care Peer Comparison (MAZE vs. NVAX, COAG, REPL, ALVO)
Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Maze Therapeutics Inc. (MAZE) ranks #473 by composite RQD confidence (45/100, grade D) and #279 by equity capitalization ($1.77B). Within this direct 5-issuer industry benchmark cohort, NVAX leads on earnings valuation at 3.9x trailing P/E, while NVAX leads on capital efficiency and profitability with 85.0% ROIC and 93.5% gross margin. ALVO currently holds the highest overall quantitative score in the immediate peer group at 58/100 (D+) compared with MAZE at 45/100 (D).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| MAZE
ACTIVE
Maze Therapeutics Inc. | D | 45/100 | — | — | -35.0% | +0.63% | $1.77B | Benchmark Subject |
| NVAX Novavax Inc. | D+ | 56/100 | 3.9x | 93.5% | 85.0% | +1.45% | $1.73B | /nvax-vs-maze → |
| COAG Hemab Therapeutics Holdings Inc. | D+ | 57/100 | — | — | — | +4.99% | $1.89B | /coag-vs-maze → |
| REPL Replimune Group Inc. | D | 46/100 | — | — | -35.0% | +8.28% | $1.65B | /repl-vs-maze → |
| ALVO Alvotech | D+ | 58/100 | — | — | — | -1.01% | $1.91B | /alvo-vs-maze → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2024–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001842295In its most recent audited fiscal period (FY2025, filed 2025-12-31), Maze Therapeutics Inc. (MAZE) reported GAAP revenue of $0 (-100.0% vs. FY2024 revenue of $167.5M ) , GAAP net income of -$131.1M, operating cash flow of -$111.9M, and free cash flow of -$112.7M (-250.7% YoY). On the balance sheet, MAZE closed FY2025 with $397.1M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $0 | -$131.1M | -$111.9M | -$112.7M | $397.1M | — |
| FY2024 (FY) | 2024-12-31 | $167.5M | $52.2M | $76.0M | $74.8M | $240.5M | — |
3. MAZE Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs MAZE stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-01, Maze Therapeutics Inc. (NASDAQ: MAZE) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 45/100 at a spot price of $31.93 (+0.63% 1D, market cap $1.77B). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 13/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 12/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, MAZE ranks #473 in composite RQD confidence.
How does MAZE compare to NVAX and COAG in the Health Care sector?
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), MAZE carries a Roarable D (45/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, NVAX (Novavax Inc.) holds a D+ grade (56/100 RQD, P/E 3.9x, ROIC 85.0%, cap $1.73B) and COAG (Hemab Therapeutics Holdings Inc.) posts a D+ grade (57/100 RQD, P/E N/A, ROIC —, cap $1.89B). Among the 5-stock peer group, NVAX leads on earnings multiple (3.9x) while NVAX leads on capital efficiency (85.0% ROIC).
What are the biggest fundamental strengths and SEC risk factors for MAZE?
Per MAZE's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001842295), Maze Therapeutics Inc. generated $0 in revenue (-100.0% YoY), -$131.1M in net income, and -$112.7M in free cash flow against $397.1M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is MAZE trading relative to its 50-day, 200-day, and 52-week technical levels?
MAZE last traded at $31.93 (+0.63% on volume of 417,943 shares), positioning the stock +16.15% above its 50-day simple moving average ($27.49) and +0.25% above its 200-day simple moving average ($31.85). Across its 52-week range of $21.95 to $53.65, MAZE sits at the 31.5% percentile with a 14-day RSI of 63.3 (BULLISH MOMENTUM) and an implied next-earnings move of ±11.5% ($28.26 to $35.60).
MAZE Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is MAZE stock moving today?
Why MAZE Stock advanced +0.63% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.